HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part D2 – AD brain scans – metabolism - PET NUCLEAR MEDICINE.

Slides:

Advertisements

Similar presentations

Developing a Chronic Disease Model of Care for Coronary Artery Disease and Depression in Rural Settings Dr Steve Bunker Prof James Dunbar Dr Prasuna Reddy.

Advertisements

Independent Research Presentation Vaibhav Garg, PD 1 “Happy is he who gets to know the reasons for things.” -- Virgil (70-19 BCE Roman Poet)

HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part D1 – AD brain scans – perfusion SPECT NUCLEAR MEDICINE.

Decreased Nuclear Receptor Activity Mediates Downregulation of Drug Metabolizing Enzymes in Chronic Kidney Disease Through Epigenetic Modulation October.

APOE Genotype Effects on Alzheimer’s Disease Clinical Onset, Epidemiology, and Gompertzian Aging Functions J.Wesson Ashford, M.D., Ph.D. Stanford / VA.

Speed of processing, the missing measure in early detection of MCI? Ruth O’Hara March 13 th 2001 Yogesh Shah.

Careers in Professional Geropsychology Professional Geropsychology Synarchy: A co-ordinating group of organizations in psychology and aging January 2013.

TESTING A LEPTIN PRODUCT AS A NOVEL THERAPY FOR ALZHEIMER’S DISEASE

Indianapolis Discovery Network for Dementia Enhancing Care for Older Adults with Acute & Chronic CI Malaz Boustani, MD, MPH.

MemTrax (Computerized Memory Screen) American Association of Geriatric Psychiatry (AAGP) March 2, 2007 J. Wesson Ashford, M.D., Ph.D. Stanford / VA Aging.

Alzheimer’s disease Aging and Health National Institute for Longevity Sciences, Japan Neuroscience Research Institute, Peking University Department of.

Office of Public Health Ansgar Furst, Ph.D. Director of Neuroimaging Laboratory, WRIISC VA Palo Alto, CA Clinical Assistant Professor (Affiliated) of Psychiatry.

BERG SYMPOSIUM WASHINGTON UNIVERSITY SEPT 2003 MICHAEL W WEINER MD.

Alzheimer's disease By: Angelyn Johnson.

Institute on Aging University of Pennsylvania Alternative Funding Strategies and the Power of Fundraising John Q. Trojanowski, M.D., Ph.D. Institute on.

HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part A – AD definition, neuropath? NUCLEAR MEDICINE GRAND.

Aging Clinical Research Center Brain Imaging Studies: Gender Effects Ruth O’Hara Assistant Professor, Department of Psychiatry and Behavioral Sciences,

How To Improve Memory Performance and Keep Your Brain Young Gary W. Small, MD Parlow-Solomon Professor on Aging Professor of Psychiatry & Biobehavioral.

Why are White Nursing Home Residents Twice as Likely as African Americans to Have an Advance Directive? Understanding Ethnic Differences in Advance Care.

ALZHEIMER PATHOLOGY AND NEUROPLASTICITY AD ATTACKS NEUROPLASTIC MECHANISMS NEUROPLASTICITY AS THE FOCUS OF THE ALZHEMIER ATTACK ALZHEIMER ATTACK AS A MODEL.

Delusions, behavioural symptoms, quality of life and caregiver effects in AD Delusions, behavioural symptoms, quality of life and caregiver effects in.

Statistical Issues for Developing Alzheimer Screening Tests J. Wesson Ashford, M.D., Ph.D. Stanford / VA Alzheimer’s Center VAMC, Palo Alto, California.

Dementia: Delivering the Diagnosis Daniel D. Christensen, M.D. Clinical Professor of Psychiatry Clinical Professor of Neurology Adjunct Professor of Pharmacology.

Six Steps to a Better Brain Majid Fotuhi, MD PhD March 6, 2014.

1 From Cause to Movement Shaping a World Without Alzheimer’s Through Advocacy, Volunteerism, Referral and Science Ian Kremer, Esq. Advocacy & Outreach.

Alzheimer’s Disease  Goals  To understand what dementia is  To explore causes, risk factors, symptoms, and treatments of Alzheimer’s Disease  To better.

Follow Up Questions Diabetes is caused by an increase in blood glucose. People with diabetes II also have a very high risk for developing Alzheimer’s disease.

Mental Health Insurance, Parity & Public Policy Richard Scheffler, Ph.D., Distinguished Professor of Health Economics and Public Policy at UC Berkeley.

HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part C – AD brain scans - anatomical NUCLEAR MEDICINE GRAND.

What is Alzheimer’s Disease?. Neurons and Neurotransmitters Neurons are cells inside the brains. Chemical transmitters (neurotransmitters) which transport.

Body Text Add description of study, duration, compensation, or any other information necessary to explain the study and the responsibilities of the participants.

Reconceptualizing Complex and Persistent Pain Bob Isler, PT Providence Persistent Pain Project and Rehabilitation Services.

Quality Improvement HIT Design to Support Teamwork and Communication Lecture b This material (Comp12_Unit7b) was developed by Johns Hopkins University,

Neurobiology of Dementia Majid Barekatain, M.D., Associate Professor of Psychiatry Neuropsychiatrist Isfahan University of Medical Sciences Ordibehesht.

The Path to a Successful Career in Academic Medicine Thomas R. Martin, M.D. Professor and Chief of Medicine VA Puget Sound Health Care System University.

Structural and Functional Neuroimaging in the Diagnosis of Dementia John M. Ringman, M.D. Assistant Professor UCLA Department of Neurology.

HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part B – AD and brain systems NUCLEAR MEDICINE GRAND ROUNDS.

ALZHEIMER’S DISEASE DIAGNOSIS and TREATMENT J. Wesson Ashford, M.D., Ph.D. Stanford / VA Alzheimer’s Center VAMC, Palo Alto, California October, 2004 Slides.

CASES SERIES BRAIN FDG PET SCAN IN DEMENTIA PATIENTS

Vipin Kumar Regents Professor and William Norris Chair in Large Scale Computing Research interests – Data mining, – high-performance computing, and – their.

Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Intranasal Insulin Therapy for Alzheimer Disease and.

Patient Experience of Care Surveys

Use of Amyloid PET Scan in Early Diagnosis of Alzheimer’s Disease in a Secondary Care Memory Clinic Niki Schoonenboom, MD PhD1, Mohammed Akarriou, MD2;

Ochronotic pigmentation of the femur of a 56-year-old alkaptonuric patient. (Courtesy of Dr. H. W. Edmonds of the Washington Hospital Center, Washington,

Coronal PET-CT scans in an 18-yr-old woman performed 6 mo apart.

Substance Use Disorders in People Living with HIV

Professor of Clinical Psychiatry

Dr Annegret Schneider Research interest:

Early Dementia Distinguishing AD From MCI

Health Services Research Postdoctoral Fellowship

Volume 10, Issue 3, Pages (January 2015)

Probing the Biology of Alzheimer's Disease in Mice

Using Technology to Expand Access to Evidence-Based Therapy

Adam P. Spira, Ph.D. Associate Professor, Department of Mental Health

Gerry Maitland Clinical Sciences

A patient with early Alzheimer disease, 77 years of age, Mini-Mental State Examination score = 25. A patient with early Alzheimer disease, 77 years of.

Updated: 29/11/2018 Number of responses: 22

Figure 4 11C-PK11195-PET scans showing the evolution of neuroinflammation in a patient after stroke Figure 4 | 11C-PK11195-PET scans showing the evolution.

Figure 1 [18F]florbetapir standardized uptake value ratio analytical method [18F]florbetapir standardized uptake value ratio analytical method Flowchart.

An 8-week open label trial of l-Threonic Acid Magnesium Salt in patients with mild to moderate dementia Tonita E. Wroolie, Kewei Chen, Kathleen T. Watson,

Figure 2 Neuroimaging characteristics of TARDBP carriers

A 53-year-old male patient with temporal lobe epilepsy (case 31).

Patient-Centered Clinical Method

A: Brain regions in the PET study where insulin-stimulated GU was measured in carriers and noncarriers of the p.P50T/AKT2 variant. A: Brain regions in.

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Figure 2 Aβ-PET scans obtained using different tracers

Electrical impedance tomographic (EIT) images are created using a series of electrodes placed across the chest, each of which send and receive electrical.

Examples of imaging data in patients.

ROC curve for the TYM-MCI, ACE-R and MMSE in the separation of patients with aMCI/AD from those with SMC. ACE-R, Addenbrooke’s Cognitive Examinations;

Box plot showing the distribution of the TYM-MCI score for patients with SMC and aMCI/AD. aMCI/AD, amnestic mild cognitive impairment or Alzheimer’s disease;

Presentation transcript:

HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part D2 – AD brain scans – metabolism - PET NUCLEAR MEDICINE GRAND ROUNDS Stanford University J. Wesson Ashford, M.D., Ph.D. Clinical Professor (affiliated), Department of Psychiatry and Behavioral Sciences Senior Research Scientist, Stanford / VA Aging Clinical Research Stanford University and VA Palo Alto Health Care System January 5, 2010 Slides at: (Dr. Ashford’s lectures)

Minoshima et al., 1997

Courtesy of S. Minoshima, University of Washington FDG-PET in AD and MCI

Regions of the Brain with Reduced Rates of Glucose Metabolism in 11 e4 Homozygotes and Their Relation to Brain Regions with Reduced Glucose Metabolism in 37 Patients with Probable Alzheimer's Disease. Reiman et al., 1996 The purple areas are regions in which glucose metabolism was significantly reduced only in the group with probable Alzheimer's disease, the blue areas regions in which glucose metabolism was significantly reduced in both the 4 homozygotes and the patients with probable Alzheimer's disease, and the green areas regions in which glucose metabolism was significantly reduced only in the 4 homozygotes.